NCT05738850View on ClinicalTrials.gov

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

104

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions

Generalized Anxiety Disorder (GAD)Healthy Participants

Interventions

DRUG

ABBV-932

Oral Capsule

DRUG

Placebo

Oral Capsule

Trial Locations (2)

60030

Acpru /Id# 249639, Grayslake

92801-2658

Anaheim Clinical Trials LLC /ID# 254178, Anaheim

Sponsors

Lead Sponsor

Collaborators (1)

Gedeon Richter Plc.

All Listed Sponsors

collaborator

Gedeon Richter Plc.

INDUSTRY

lead

AbbVie

INDUSTRY